| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | EWTX | Common Stock | Options Exercise | $19,300 | +10,000 | +59% | $1.93 | 26,837 | 05 Feb 2025 | Direct | F1 |
| transaction | EWTX | Common Stock | Sale | $300,300 | -10,000 | -37% | $30.03 | 16,837 | 05 Feb 2025 | Direct | F2, F3 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | EWTX | Stock Option (Right to Buy) | Options Exercise | $0 | -10,000 | -9.7% | $0.000000 | 92,929 | 05 Feb 2025 | Common Stock | 10,000 | $1.93 | Direct |
| Id | Content |
|---|---|
| F1 | Includes 1,716 shares purchased on November 15, 2024 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. |
| F2 | The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 30, 2024. |
| F3 | The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.13, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |